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Kaposi's sarcoma-associated herpesvirus (KSHV), also
called human herpesvirus-8 (HHV-8), is an oncogenic
gammaherpesvirus associated with Kaposi's sarcoma
(KS), primary effusion lymphoma (PEL), and a form of
MCD. KSHV-associated MCD (KSHV-MCD) is a rare B-
cell lymphoproliferative disease almost universally found
in association with HIV infection that is characterized by
a recurrent systemic syndrome of fatigue, fevers, cytope-
nias, elevated serum C-reactive protein (CRP), and lytic
KSHV replication with production of a virally-encoded
interleukin-6 (vIL-6). There is no standard therapy for
KSHV-MCD although there are reports of patients
responding to a variety of agents including interferon
alpha, cytotoxic chemotherapy, rituximab or ganciclovir.
Overall, the prognosis is poor (median survival 14
months). KSHV open reading frames (ORF) 21 and 36
respectively have the ability to phosphorylate zidovudine
and ganciclovir to toxic triphosphate moieties. We found
that when these lytic genes are activated in PEL cell lines,
as by hypoxia, the cells can be killed by concentrations of
these drugs that are clinically attainable (Cancer Res 2007;
67:7003–7010).
We have explored the translation of these observations to
the clinic in MCD, taking advantage of lytic KSHV replica-
tion already present in the tumor cells. Ten patients with
symptomatic biopsy-confirmed KSHV-MCD were treated
with high dose oral zidovudine (HDAZT), 600 mg every 6
hours, and valganciclovir (VGCV), 900 mg every 12
hours; the protocol was approved by the NCI Institutional
Review Board and all patients gave informed consent.
Treatment length of the first cycle was dependent on
response, and ranged from 7–21 days. Subsequent cycle
length was 21 days with treatment administered during
the first 7 days. Treatment was stopped when patients
achieved a complete response (CR) or plateau in
response. Patient characteristics were: median age 40
(range 33–56); ECOG PS 2 (1–3); median enrollment
CD4 count 189 (range 19–1319 UL); median HIV viral
load <50 copies/ml3 plasma (range <50 to 27,500). All
patients were on combination antiretroviral therapy; this
was adjusted during the time patients were on AZT. Eight
patients had a history of KS. Median duration of MCD was
3.5 months (range 0.5–45 months); seven patients had
received at least one prior therapy for MCD (range 1–6).
All had MCD-related constitutional symptoms and CRP
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above 0.8 mg/dl (median 13.1, range 1.06–38.7 mg/dl) at
treatment initiation. A total of 112 cycles have been
administered to date, with a median of 10 (range 3–29)
cycles per patient.
Nine of 10 patients had documented improvement in
constitutional symptoms, C-reactive protein levels or
cytopenias. Five patients achieved an objective response
as defined by the protocol (two CR and three partial
remissions). The median survival has not been reached;
the 12 month probability of survival is 70 percent, and
patients remain alive from 12.5 to 32 months. The
median PFS is 5.4 months; two patients have not yet pro-
gressed after 15.5 and 27 months on study. Seven patients
remain alive. Treatment was well tolerated; toxicity
included two patients with fatigue (grade [gr] 3), one with
nausea (gr3), one with transaminitis (gr3) and one with
insomnia (gr3). Grade 3 or 4 hematologic toxicity not
attributable to disease was seen in only two patients. Two
patients developed KSHV-associated lymphoma. Three
infectious events occurred, a staphylococcal skin abscess,
streptococcal meningitis and a streptococcal pneumonia.
There were no neutropenia-associated infections. In sum-
mary, this preliminary data suggests that the combination
of HDAZT and VGCV is well tolerated and has activity in
patients with KSHV-MCD. Accrual continues.
Acknowledgements
This research was supported by the Intramural Research Program of the 
NIH, NCI.Page 2 of 2
(page number not for citation purposes)
